1. Home
  2. Clinical Topics
  3. First FDA approved treatment for thyroid eye disease
Clinical TopicsDrugs and DevicesNewsOphthalmology

First FDA approved treatment for thyroid eye disease

Share
By: Lydia L. Kim, Digital Content Editor

The U.S. Food and Drug Administration (FDA) recently approved Horizon Therapeutics Ireland DAC’s teprotumumab-trbw (Tepezza) as the first FDA-approved treatment for adults with thyroid eye disease (TED).

TED is a rare disorder which causes the fatty tissues and muscles behind a person’s eyes to become so inflamed, that it causes the eyes to push forward to the point of bulging out. This can lead to several more impactful symptoms, including eye pain and vision impairment.

The deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research describes the impact of this approval: “Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non surgical treatment option…Additionally, thyroid eye disease is a rare disease that impacts a small percentage of the population, and for a variety of reasons, treatments for rare diseases are often unavailable. This approval represents important progress in the approval of effective treatments for rare diseases, such as thyroid eye disease.”

The approval also speaks to the FDA’s mission to help advance the quality of care for patients and their families who suffer from rare disorders.

Please read more about teprotumumab-trbw’s approval here.

Source:
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts